ClassID:

109967

C12N2710/20071 - CPC Classification

Classification description:

dsDNA viruses; Details; Papillomaviridae Demonstrated effect

Recent Application in this class:
#1
20250170235
2025-05-29

MESSENGER RIBONUCLEIC ACIDS FOR ENHANCING IMMUNE RESPONSES AND METHODS OF USE THEREOF

#2
20240216502
2024-07-04

Universal vaccine platform

#3
20240130973
2024-04-25

Compositions, methods and uses for thermally stable multi-targeted antigens

#4
20240100141
2024-03-28

T CELL-DIRECTED ANTI-CANCER VACCINES AGAINST COMMENSAL VIRUSES FOR TREATING MUCOSAL CARCINOMAS

#5
20240092840
2024-03-21

VACCINE FORMULATION COMPRISING RECOMBINANT OVERLAPPING PEPTIDES AND NATIVE PROTEINS

#6
20240002447
2024-01-04

MODIFIED HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN AND USE THEREOF

#7
20230210970
2023-07-06

HETEROLOGOUS COMBINATION PRIME:BOOST THERAPY AND METHODS OF TREATMENT

#8
20220251574
2022-08-11

CELL CAPABLE OF ACTIVATING IMMUNE SYSTEM, AND PHARMACEUTICAL COMPOSITION CONTAINING SAID CELL

#9
20220175907
2022-06-09

Compositions, methods and uses for thermally stable multi-targeted antigens

#10
20220152217
2022-05-19

TARGETED COMBINATION THERAPY

#11
20210330785
2021-10-28

Universal vaccine platform

#12
20210252138
2021-08-19

HPV vaccine

#13
20210246457
2021-08-12

Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof

#14
20210228703
2021-07-29

Mutant of L1 protein of human papillomavirus type 18

#15
20210052712
2021-02-25

HETEROLOGOUS COMBINATION PRIME:BOOST THERAPY AND METHODS OF TREATMENT

#16
20200261572
2020-08-20

MESSENGER RIBONUCLEIC ACIDS FOR ENHANCING IMMUNE RESPONSES AND METHODS OF USE THEREOF

#17
20200164057
2020-05-28

Therapeutic HPV16 vaccines

#18
20200109160
2020-04-09

Lipid A mimics, methods of preparation, and uses thereof

#19
20200085943
2020-03-19

Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen

#20
20200038505
2020-02-06

Virus-like particle compositions and vaccines against epstein-barr virus infection and disease

#21
20190336596
2019-11-07

Universal vaccine platform

#22
20190142933
2019-05-16

Therapeutic HPV vaccine combinations

#23
20190133954
2019-05-09

Compositions, methods and uses for thermally stable multi-targeted antigens

#24
20190062379
2019-02-28

Mutant of L1 protein of human papillomavirus type 11

#25
20190002891
2019-01-03

Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof

#26
20180344841
2018-12-06

Therapeutic HPV16 vaccines

#27
20180311343
2018-11-01

MESSENGER RIBONUCLEIC ACIDS FOR ENHANCING IMMUNE RESPONSES AND METHODS OF USE THEREOF

#28
20180311340
2018-11-01

NEW ADJUVANT AND VACCINE COMPOSITION CONTAINING THE SAME

#29
20180296662
2018-10-18

Sexually transmitted disease vaccines

#30
20180237477
2018-08-23

POLYNUCLEOTIDES FOR TREATING ONCOGENIC VIRAL POLYPEPTIDE POSITIVE TUMORS

#31
20180111964
2018-04-26

Fusion polypeptide for immuno-enhancement and method for enhancing stimulation of immune response using the same

#32
20180094032
2018-04-05

HPV16 non HLA-restricted t-cell vaccines, compositions and methods of use thereof

#33
20180078634
2018-03-22

Virus-like particle compositions and vaccines against Epstein-Barr virus infection and disease

#34
20180050105
2018-02-22

PCI method for generating immune respose to antigenic molecule using checkpoint inhibitor and TLR3 ligand

#35
20180009833
2018-01-11

Lipid A mimics, methods of preparation, and uses thereof

#36
20170349633
2017-12-07

HPV-related fusion protein and applications thereof

#37
20170304385
2017-10-26

Methods of treating cervical cancer

#38
20170281747
2017-10-05

Therapeutic HPV16 vaccines

#39
20170252417
2017-09-07

PROTEIN-CHAPERONED T-CELL VACCINES

#40
20170165351
2017-06-15

Method and composition for treating cancer or skin lesion using a vaccine

#41
20170112760
2017-04-27

CELL DELIVERY SYSTEM AND METHOD

#42
20170080064
2017-03-23

METHODS AND COMPOSITIONS FOR INCREASING A T-EFFECTOR CELL TO REGULATORY T CELL RATIO

#43
20170065715
2017-03-09

Vaccine compositions comprising a saponin adjuvant

#44
20170065705
2017-03-09

Adenoviral vector vaccine

#45
20160376324
2016-12-29

Polynucleotides for treating oncogenic viral polypeptide positive tumors

#46
20160324952
2016-11-10

Immunity enhancing therapeutic vaccine for HPV and related diseases

#47
20160250324
2016-09-01

Vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific T-cell responses

#48
20160243213
2016-08-25

Recombinant protein bodies as immunogen-specific adjuvants

#49
20160228532
2016-08-11

Method of obtaining thermostable dried vaccine formulations

#50
20160122396
2016-05-05

Therapeutic HPV16 vaccines

#51
20160114023
2016-04-28

Cancer and skin lesion treatment

#52
20150306217
2015-10-29

Vaccines against HPV

#53
20150291665
2015-10-15

Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response

#54
20150118264
2015-04-30

PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN

#55
20150110824
2015-04-23

METHOD OF VACCINATION AGAINST HUMAN PAPILLOMAVIRUS

#56
20150056197
2015-02-26

VACCINES AGAINST HPV

#57
20150023996
2015-01-22

Polynucleotides for treating oncogenic viral polypeptide positive tumors

#58
20120276148
2012-11-01

Methods of generating immune responses with compositions comprising an adenoviral expression vector comprising a CD40L fusion protein

#59
20120195924
2012-08-02

Composition comprising an adenoviral expression vector comprising a CD40L fusion protein for generating immune responses

#60
20120040367
2012-02-16

CONSTRUCT SYSTEM AND USES THEREFOR

#61
20110262478
2011-10-27

Recombinant Protein Bodies as Immunogen-Specific Adjuvants

#62
20110206758
2011-08-25

Vaccine compositions comprising a saponin adjuvant

#63
20110135680
2011-06-09

Deletion mutants of flagellin and methods of use

#64
20110020374
2011-01-27

Expression system for modulating an immune response

#65
20100150999
2010-06-17

THERAPY OF CANCER BASED ON TARGETING ADAPTIVE, INNATE AND/OR REGULATORY COMPONENT OF THE IMMUNE RESPONSE

#66
20080279926
2008-11-13

Vaccine Compositions Comprising a Saponin Adjuvant

#67
20080152665
2008-06-26

Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response

#68
20070269409
2007-11-22

Adenoviral expression vector comprising a CD40L fusion protein adapted to elicit cellular immunity